Tech Stocks Slide With Bond Yields at Decade Highs -- WSJ
Dow Jones2026/08/18 18:00By Alexander Osipovich
Stocks are in the red and borrowing costs around the world are at multiyear highs, as investors fret over heavy fiscal spending and inflation.
The 30-year U.S. Treasury yield is hovering near 5.3% after hitting a 19-year intraday high earlier in the day; Japanese long-dated yields are close to a record high. One factor pushing up bond yields: The capital-hungry AI industry's huge appetite for debt, which puts it in competition with traditional nation-state borrowers.
Equities are also struggling, with the Nasdaq down over 1%. Chip stocks are getting hit hard, with the PHLX Semiconductor index down more than 5% and some of its components (Intel, Marvell, ARM Holdings, Coherent, and Teradyne) down 7% or more.
Renewed tensions in the Middle East are weighing on markets. An unknown projectile struck a cargo ship in the Strait of Hormuz overnight, the British navy's marine-traffic monitoring agency said.
The attack came after a 60-day truce between the U.S. and Iran expired yesterday with few signs of progress towards a permanent deal to replace it. President Trump wrote this morning that no talks are planned with Iran.
Brent crude oil prices are hovering around $91 a barrel.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
August 18, 2026 14:00 ET (18:00 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs: Concern over "profit bubble" is exaggerated, S&P 500 could rise to 8,700 points next year
Goldman Sachs predicts that corporate earnings will grow by 11% next year, which could drive the S&P 500 index up by 14% over the next year to around 8,700 points.
US Dollar: Oil drives Dollar upside risks – ING
BlossomHill Therapeutics Q2 Loss Widens